

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for detecting non-responders to anti-TNF therapy with a TNF-binding protein that interferes with TNF binding to a TNF Receptor II, comprising testing an individual for homozygosity for at least one single nucleotide polymorphism in the nucleotide substitution A/G at position 168 from a transcription starting site in exon 2 of a gene coding for the TNF Receptor II.
2. (Currently Amended) The method of claim 1, wherein ~~anti-TNF therapy is infliximab therapy~~ the TNF-binding protein that interferes with TNF binding to a TNF Receptor II is infliximab.
3. (Currently Amended) The method of claim 1, wherein the anti-TNF therapy is therapy of Crohn's disease.
- 4-9. (Canceled)
10. (Currently Amended) A method of diagnosis comprising[[:]] using a polymorphism at position 168 (A/G) in exon 2 of [[the]] a gene coding for [[the]] a TNF Receptor II to detect non-responders to anti-TNF therapy with a TNF-binding protein that interferes with TNF binding to the TNF Receptor II.
11. (Currently Amended) The method of claim 10 ~~in an inflammatory or malignant or other chronic disease~~, wherein the TNF-binding protein that interferes with TNF binding to a TNF Receptor II is infliximab.
12. (Currently Amended) The method of claim 11 ~~in Crohn's disease~~, wherein the anti-TNF therapy is therapy of Crohn's disease.
- 13-22. (Canceled)